| Name | PF-04620110 |
| Description | PF-04620110 is an orally active, selective and potent diglyceride acyltransferase-1 (DGAT1) inhibitor with IC50 of 19 nM. |
| In vitro | Ampiroxicam (<150 μM) dose-dependently decreases the proliferation of Panc-1 cells. [1] Ampiroxicam (50 μM) results in decreased expression of Sp1, Sp3, Sp4, and VEGFR1 proteins in Panc-1 cells and L3.6pl cells as determined by Western blot analysis. Ampiroxicam (50 μM) results in increased phosphorylation of MAPK1/2 in Panc-1 cells and L3.6pl cells. [2] |
| In vivo | In Rats, PF-04620110 reduces plasma triglyceride levels t doses of ≥0.1 mg/kg following a lipid challenge. [1] DGAT1 inhibition by PF-04620110 causes an enrichment of polyunsaturated fatty acids within the TG class of lipids in rodents. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 19.8 mg/mL (49.94 mM), Sonication and heating are recommended.
|
| Keywords | PF-04620110 | mono- acylglycerol acyltransferase | Inhibitor | inhibit | Diglyceride acyltransferase | Diacylglycerol acyltransferase | DGAT1 | Acyltransferase | acyl-CoA:cholesterol acyltransferase |
| Inhibitors Related | Alendronate sodium trihydrate | Serotonin hydrochloride | Serotonin | D(+)-Raffinose pentahydrate | 2,2'-Methylenebis(6-tert-butyl-4-methylphenol) | Risedronic Acid | Cyclandelate | Entacapone | CBHcy | 2-Furoic acid | Flopropione | Tolcapone |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Multi-Target Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Metabolism Compound Library | Lipid Metabolism Compound Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |